FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
(NASDAQ: NVCR) Delayed: 16.53 -0.16 (0.96%)
Previous Close $16.69    52 Week High $28.95 
Open $16.87    52 Week Low $5.95 
Day High $16.87    P/E N/A 
Day Low $16.37    EPS $0.00 
Volume 633,460